Universal Health (UHS) AI Stock Analysis

• Market Cap: $11.89B
• Dividend Yield: 0.43%
• Average Volume (3M): 871.71K
• Price to Earnings (P/E): 10.4
• Beta (1Y): 0.75
• Revenue Growth: 9.73%
• EPS Growth: 51.87%
• Country: US
• Employees: 99,300
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Care Facilities
• EPS (TTM): 4.84
• Shares Outstanding: 57,189,716
• 10 Day Avg. Volume: 1,097,939
• 30 Day Avg. Volume: 871,706
• PEG Ratio: 0.16
• Price to Book (P/B): 1.77
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 10.63
• Enterprise Value/Market Cap: 1.41
• Enterprise Value/Revenue: 0.27
• Enterprise Value/Gross Profit: 1.78
• Enterprise Value/Ebitda: 1.92
• 1Y Price Target: $229.09
• Price Target Upside: 24.15% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 12

• Rating: 77 Outperform
• Price Target: $206.00 ▲(11.63%Upside)

Universal Health Services shows strong financial performance with consistent revenue growth and profitability. Technical indicators suggest short-term positive momentum, though long-term caution is warranted. Valuation metrics indicate the stock is undervalued, supporting investment appeal. The earnings call reinforces confidence despite some cash flow and regulatory uncertainties.

Positive Factors

Earnings

Adjusted EPS of $4.84 beat Street estimates by 11%.

Operational Performance

West Henderson is already generating positive EBITDA which should offset Cedar Hill losses in the second half.

Valuation

The stock is trading toward the low end of its valuation, suggesting potential for upward movement.

Negative Factors

Analyst Expectations

Quarterly EBITDA estimates for UHS appear too high and are being adjusted downwards.

Cost Management

Start-up costs likely higher with the Cedar Hill Hospital in DC opening, leading to increased costs before improving in the second half.

Volume Growth

Behavioral volumes were soft with no volume growth, attributed to calendar headwinds and winter weather impacting referrals.

Universal Health Business Overview & Revenue Model

Company Description

Universal Health Services, Inc., through its subsidiaries, owns and operates acute care hospitals, and outpatient and behavioral health care facilities. The company operates through Acute Care Hospital Services and Behavioral Health Care Services segments. Its hospitals offer general and specialty surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic and coronary care, pediatric services, pharmacy services, and/or behavioral health services. As of February 24, 2022, it owned and/or operated 363 inpatient facilities, and 40 outpatient and other facilities located in 39 states; Washington, D.C.; the United Kingdom; and Puerto Rico. The company also provides commercial health insurance services; and various management services, which include central purchasing, information, finance and control systems, facilities planning, physician recruitment, administrative personnel management, marketing, and public relations services. Universal Health Services, Inc. founded in 1978 and is headquartered in King of Prussia, Pennsylvania.

How the Company Makes Money

Universal Health Services, Inc. generates revenue through its network of acute care hospitals and behavioral health facilities. The primary revenue streams include patient service revenues, which are derived from hospital admissions, outpatient consultations, and various healthcare services provided to patients. UHS also benefits from contracts with government programs like Medicare and Medicaid, as well as agreements with private health insurance companies. The company collaborates with insurers and other healthcare providers to expand its service reach and enhance patient care, which contributes significantly to its earnings. Additionally, UHS's strategic acquisitions and expansions into new markets provide avenues for increased revenue and market share.

Universal Health Financial Statement Overview

Summary

Universal Health exhibits strong financial health characterized by consistent revenue growth, robust profitability, and effective cash flow management. The company maintains a healthy equity ratio and strong cash flows, although leverage is moderate.

Income Statement

Universal Health has demonstrated consistent revenue growth with a notable increase in total revenue from $11.56 billion in 2020 to $16.08 billion in TTM 2025. The gross profit margin remains robust, indicating effective cost management. Net profit margin has improved, reflecting enhanced operational efficiency. EBIT and EBITDA margins are strong, indicating solid profitability in core operations.

Balance Sheet

The company maintains a healthy equity ratio, with stockholders' equity consistently representing a substantial portion of total assets. The debt-to-equity ratio shows moderate leverage, which is manageable given the company's strong equity base. Return on equity is improving, demonstrating effective use of equity capital.

Cash Flow

Operating cash flow is strong, consistently exceeding net income, indicating good cash conversion. Free cash flow has grown significantly, supporting further investment and debt management. The cash flow metrics reflect strong financial health with ample liquidity to support operations and strategic initiatives.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.08B	15.83B	14.28B	13.40B	12.64B	11.56B
Gross Profit	9.40B	14.24B	12.75B	11.93B	11.21B	10.27B
EBITDA	2.34B	2.27B	1.74B	1.58B	1.91B	1.87B
Net Income	1.20B	1.14B	717.79M	675.61M	991.59M	943.95M
Balance Sheet
Total Assets	14.88B	14.47B	13.97B	13.49B	13.09B	13.48B
Cash, Cash Equivalents and Short-Term Investments	126.75M	125.98M	119.44M	102.82M	115.30M	1.22B
Total Debt	5.09B	4.96B	5.37B	5.27B	4.56B	4.19B
Total Liabilities	7.99B	7.71B	7.77B	7.52B	6.90B	7.07B
Stockholders Equity	6.87B	6.75B	6.15B	5.92B	6.09B	6.32B
Cash Flow
Free Cash Flow	1.06B	1.12B	524.74M	262.02M	28.04M	1.63B
Operating Cash Flow	2.03B	2.07B	1.27B	996.02M	883.70M	2.36B
Investing Cash Flow	-987.77M	-911.11M	-763.27M	-647.30M	-914.47M	-802.56M
Financing Cash Flow	-1.03B	-1.14B	-493.94M	-318.40M	-1.07B	-384.86M

Universal Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 184.53
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UHS, the sentiment is Positive. The current price of 184.53 is above the 20-day moving average (MA) of 177.50, above the 50-day MA of 181.94, and below the 200-day MA of 191.24, indicating a neutral trend. The MACD of 0.14 indicates Negative momentum. The RSI at 56.67 is Neutral, neither overbought nor oversold. The STOCH value of 83.02 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UHS.

Universal Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UHS	77 Outperform	$11.89B	10.36	18.35%	0.43%	9.73%	51.87%
EHC	75 Outperform	$11.98B	24.54	25.33%	0.57%	11.21%	30.38%
MOH	72 Outperform	$12.99B	11.57	26.72%	―	16.71%	12.23%
MEDP	72 Outperform	$9.24B	24.54	65.82%	―	9.87%	32.81%
THC	71 Outperform	$15.93B	11.34	38.12%	―	-1.79%	-41.85%
ACHC	60 Neutral	$2.15B	11.47	6.35%	―	5.48%	―
Sector *	52 Neutral	$7.50B	0.31	-61.87%	2.27%	17.10%	1.59%

Universal Health Corporate Events

Universal Health Holds Annual Stockholders Meeting

On May 14, 2025, Universal Health held its Annual Meeting of Stockholders virtually. During the meeting, stockholders elected two Class II members to the Board of Directors for a term ending in 2028, ratified PricewaterhouseCoopers, LLP as the independent accounting firm for 2025, and voted against a proposal for annual director elections.

The most recent analyst rating on (UHS) stock is a Buy with a $240.00 price target. To see the full list of analyst forecasts on Universal Health stock, see the UHS Stock Forecast page.